# US 2016/0250145 A1 · Rapidly Dispersible Dosage Form of Oxcarbazepine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250145 A1
- Document ID: US20160250145A1
- Status: Published application
- Kind: A1
- Application number: 15/045,711
- Filed: 2016-02-17
- Published: 2016-09-01
- Earliest claimed: 2013-03-15
- Assignees: Aprecia Pharmaceuticals LLC
- Applicants: Aprecia Pharmaceuticals Company
- Inventors: Jules JACOB; Kelly CAPUTO; Micael GUILLOT; Kenneth J. SULTZBAUGH; Thomas G. WEST
- Web page: https://patentgrep.com/patent/US20160250145A1

## CPC

- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 9/1694: {resulting in granules or microspheres of the matrix type containing more than 5% of excipient}
- A61K 9/2009: {Inorganic compounds}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2077: {Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets}
- A61K 9/2095: {Tabletting processes}
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61P 25/08: Antiepileptics; Anticonvulsants
- B29C 64/165: using a combination of solid and fluid materials, e.g. a powder selectively bound by a liquid binder, catalyst, inhibitor or energy absorber
- B33Y 10/00: Processes of additive manufacturing
- B33Y 70/00: Materials specially adapted for additive manufacturing
- B33Y 80/00: Products made by additive manufacturing
- A61K 9/1611: {Inorganic compounds}
- A61K 9/1617: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/1623: {Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules}
- A61K 9/1635: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/7007: {Drug-containing films, membranes or sheets (A61K9/0041, A61K9/0043, A61K9/006, A61K9/0063 take precedence)}
- B29K 2105/0035: {Medical or pharmaceutical agents}
- B29K 2105/0058: {Liquid or visquous}
- B29K 2105/251: {Particles, powder or granules (expandable particles B29K2105/046)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B29C: SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING (making preforms B29B11/00; making laminated products by combining previously unconnected layers which become one product whose layers will remain together B32B37/00 - B32B41/00)
- B33Y: ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B29K: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR {MOULDS, } REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS

## Abstract

A high dose orodispersible dosage form of oxcarbazepine is provided. Drug-containing particles of oxcarbazepine are included within a porous bound matrix. The dosage form disperses in saliva or water in less than 15 sec and it has sufficient hardness to withstand handling and storage. It can be used to treat diseases or disorders that are therapeutically responsive to oxcarbazepine or a derivative thereof.

## Claims

### Claim 1

1) (canceled)

### Claim 2

2) (canceled)

### Claim 3

3) (canceled)

### Claim 4

4) (canceled)

### Claim 5

5) (canceled)

### Claim 6

6) (canceled)

### Claim 7

7) (canceled)

### Claim 8

8) (canceled)

### Claim 9

9) (canceled)

### Claim 10

10) (canceled)

### Claim 11

11) (canceled)

### Claim 12

12) (canceled)

### Claim 13

13) (canceled)

### Claim 14

14) (canceled)

### Claim 15

15) A rapidly dispersible porous non-compressed three-dimensionally printed bound matrix comprising:
drug-containing particles comprising at least one first disintegrant, at least one first binder, at least one surfactant and native particles of drug, wherein the drug-containing particles have an average, mean or median effective particle size and the native particles of drug have an average, mean or median native particle size, and the ratio of average, mean or median effective particle size to average, mean or median, respectively, native particle size ranges from greater than 1:1 to 200:1;
at least one second disintegrant; and
at least one second binder;
wherein the hardness of the matrix ranges from about 1 to about 7 kiloponds.

### Claim 16 (depends on 15)

16) The matrix of claim 15, wherein the matrix disperses in 15 sec or less when placed in 15 ml of aqueous fluid.

### Claim 17 (depends on 15)

17) The matrix of claim 15, wherein the average native particle size is such that 90%-100% wt of the drug is <10 microns, and the ratio of average effective particle size to average native particle size is in the range of 10:1 to 200:1.

### Claim 18 (depends on 15)

18) The matrix of claim 15, wherein the average native particle size is such that not more than 20% wt of the drug is <32 microns, 40-70% wt of the drug is <63 microns, 70-95% wt of the drug is <125 microns, and 100% wt of the drug is <250 microns, and the ratio of average effective particle size to average native particle size is in the range of greater than 1:1 to about 10:1.

### Claim 19 (depends on 15)

19) The matrix of claim 15, wherein the native particles of drug have an average, mean or median native particle size in the range of about 1 to about 90 microns.

### Claim 20 (depends on 15)

20) The matrix of claim 15, wherein the drug-containing particles have an average, mean or median effective particle size in the range of about 50 to about 400 microns.

### Claim 21 (depends on 15)

21) The matrix of claim 15, wherein the drug is a poorly water soluble.

### Claim 22 (depends on 21)

22) The matrix of claim 21, wherein the drug is OXC.

### Claim 23 (depends on 15)

23) The matrix of claim 15, comprising:
drug-containing particles comprising at least one first disintegrant, at least one first binder, at least one surfactant, a first grade of native particles of drug and a second grade of native particles of drug, wherein the drug-containing particles have an average, mean or median effective particle size and the first grade of native particles of drug have an average, mean or median first native particle size and the second grade of native particles of drug have an average, mean or median second native particle size, and the ratio of average, mean or median effective particle size to average, mean or median, respectively, first native particle size ranges from greater than 1:1 to about 5:1, and the ratio of average, mean or median effective particle size to average, mean or median, respectively, second native particle size ranges from about 20:1 to about 50:1;
at least one second disintegrant; and
at least one second binder;
wherein the hardness of the matrix ranges from about 1 to about 7 kiloponds.

### Claim 24 (depends on 23)

24) The matrix of claim 23, wherein:
the drug-containing particles further comprise at least one sweetener and at least one glidant;
the matrix comprises particles bound by said second binder;
the matrix disperses in less than 15 sec in a volume of 15 ml of aqueous fluid; and/or
the content of drug in the matrix is 35-60% wt based upon the total weight of the matrix.

### Claim 25 (depends on 24)

25) The matrix of claim 24, wherein: a) the at least one surfactant is present in an amount of 0.5-7.0% wt based upon the final weight of the dosage form; b) the at least one sweetener is present in an amount of 0.01-2.0% wt based upon the final weight of the dosage form; c) the at least one first binder and the at least one second binder are together present in an amount of 5-15% wt based upon the final weight of the dosage form; d) the at least one first disintegrant and the at least one second disintegrant are together present in an amount of 10-30% wt based upon the final weight of the dosage form; and/or e) the at least one glidant is present in an amount of 0-2% wt based upon the final weight of the dosage form.

### Claim 26 (depends on 15)

26) The matrix of claim 15, wherein: a) the native particles of drug possess a bi-modal or multi-modal particle size distribution; b) the drug-containing particles possess a mono-modal, bi-modal or multi-modal particle size distribution; or c) a combination of one or more of the above.

### Claim 27 (depends on 15)

27) The matrix of claim 15, wherein: a) the hardness ranges from about 1 to about 3 kp; b) the matrix disperses in 10 sec or less when placed in 15 ml of water or in saliva; c) the matrix comprises about 150 mg to about 600 mg of drug; and/or d) the matrix comprises 10 to 40 three-dimensionally printed incremental layers.

### Claim 28

28) (canceled)

### Claim 29 (depends on 15)

29) The matrix of claim 15, wherein: a) the content of drug-containing particles in the matrix is 55-85% wt based upon the total weight of matrix in the final dosage form; b) the content of native particles of drug in the drug-containing particles is 55-85% wt based upon the final weight of the drug-containing particles; c) the content of first disintegrant in the drug-containing particles ranges up to 30% wt, based upon the final weight of the drug-containing particles; d) the content of first binder in the drug-containing particles ranges up to 10% wt, based upon the final weight of the drug-containing particles; e) the content of surfactant in the drug-containing particles ranges up to 10% wt, based upon the final weight of the drug-containing particles; and/or f) the drug-containing particles are manufactured by wet granulation.

### Claim 30 (depends on 15)

30) The matrix of claim 15, wherein the matrix comprises about 150 to about 1200 mg of drug.

### Claim 31 (depends on 15)

31) The matrix of claim 15, wherein the matrix has been prepared by a three-dimensional printing process employing printing fluid, drug-containing particles and bulk powder of the following compositions:
printing fluid comprising glycerin;
drug-containing particles comprising a first grade of drug native particles, the at least one first disintegrant, the at least one first binder and at least one first surfactant; and
bulk powder comprising the drug-containing particles, the at least one second disintegrant, the at least one second binder and at least one glidant.

### Claim 32 (depends on 31)

32) The matrix of claim 31, wherein the printing fluid comprises: a) glycerin and alcohol; or b) alcohol.

### Claim 33

33) (canceled)

### Claim 34 (depends on 31)

34) The matrix of claim 31, wherein:
the printing fluid comprises water, glycerin, alcohol and surfactant.

### Claim 35 (depends on 31)

35) The matrix of claim 31, wherein the matrix has been prepared by a three-dimensional printing process employing printing fluid, drug-containing particles and bulk powder of the following compositions:
Printing fluid
Water (% wt)
80-95
Glycerin (% wt)
0.5-20
Alcohol (% wt)
0.1-20
Surfactant (% wt)
0.01-10
Sweetener (% wt)
0-10
Binder (% wt)
0-10
Drug-containing particles:
Drug (% wt)
55-75
Disintegrant (% wt)
15-45
Binder (% wt)
0-10
Surfactant (% wt)
0-10
Bulk powder:
Drug containing particles (% wt)
55-65
Disintegrant (% wt)
2-15
Binder (% wt)
20-45
Glidant (% wt)
0.1-1.5

### Claim 36 (depends on 15)

36) The matrix of claim 15, wherein the matrix is shaped as a wafer, cylinder, ring, donut, tube, cube, spheroid, ellipsoid or rectangular box.

### Claim 37 (depends on 15)

37) The matrix of claim 15, wherein: a) the first binder and second binder are independently selected at each occurrence from the group consisting of polyvinylpyrrolidone, mannitol, hydroxypropylcellulose, and a combination thereof; b) the first disintegrant and the second disintegrant are independently selected at each occurrence from the group consisting of microcrystalline cellulose, a combination of two grades of microcrystalline cellulose, croscarmellose, and a combination thereof; or c) a combination of the above.

### Claim 38 (depends on 15)

38) A method of treating a disease, condition or disorder that is therapeutically responsive to the drug comprising administering the matrix of claim 15 one or more times daily to a subject in need thereof throughout a treatment period.

### Claim 39 (depends on 15)

39) The matrix of claim 15, wherein the thickness of an incremental layer ranges from 0.006 inches to 0.014 inches.

### Claim 40

40) A three-dimensionally printed bound matrix comprising:
drug-containing particles comprising at least one first binder and native particles of drug, wherein the drug-containing particles have an average, mean or median effective particle size and the native particles of drug have an average, mean or median native particle size, and the ratio of average, mean or median effective particle size to average, mean or median, respectively, native particle size ranges from greater than 1:1 to 200:1.

### Claim 41 (depends on 40)

41) The matrix of claim 40, wherein:
the drug-containing particles comprise at least one first binder, a first grade of native particles of drug and a second grade of native particles of drug, wherein the first grade of native particles of drug have an average, mean or median first native particle size and the second grade of native particles of drug have an average, mean or median second native particle size, and the average, mean or median first native particle size is smaller than the average, mean or median, respectively, second native particle size.

### Claim 42 (depends on 41)

42) The matrix of claim 41, wherein:
the drug-containing particles comprise at least one first binder, a first grade of native particles of drug and a second grade of native particles of drug, wherein the drug-containing particles have an average, mean or median effective particle size and the first grade of native particles of drug have an average, mean or median first native particle size and the second grade of native particles of drug have an average, mean or median second native particle size, and the ratio of average, mean or median effective particle size to average, mean or median, respectively, first native particle size ranges from greater than 1:1 to about 5:1, and the ratio of average, mean or median effective particle size to average, mean or median, respectively, second native particle size ranges from about 20:1 to about 50:1.

### Claim 43 (depends on 40)

43) The matrix of claim 40, wherein the bound matrix further comprises at least one second binder that binds the drug-containing particles to form the bound matrix.

### Claim 44 (depends on 40)

44) The matrix of claim 40, wherein the drug-containing particles further comprise at least one first disintegrant.

### Claim 45 (depends on 40)

45) The matrix of claim 40, wherein the bound matrix further comprises at least one second disintegrant outside the drug-containing particles.

### Claim 46 (depends on 40)

46) The matrix of claim 40, wherein the drug-containing particles are prepared by wet granulation.

### Claim 47 (depends on 15)

47) The matrix of claim 15, wherein: a) the drug-containing particles comprise at least two first disintegrants and at least one binder; b) the matrix comprises at least two second binders and at least one second disintegrant; c) a combination of any of the above.

### Claim 48 (depends on 15)

48) The matrix of claim 15, wherein: a) at least one first binder is different than the at least one second binder; b) at least one first disintegrant is different than the at least one second disintegrant; c) at least one first binder is the same as the at least one second binder; d) at least one first disintegrant is the same as the at least one second disintegrant; or e) a combination of any of the above.
